Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Conditions:   Metastatic Solid Tumor;   Colorectal Cancer;   Neuroendocrine Tumors;   Small Cell Lung Cancer;   Gastric Cancer;   Soft Tissue Sarcoma Interventions:   Drug: Surufatinib and Tislelizumab _ Part 1;   Drug: Surufatinib and Tislelizumab _ Part 2 Sponsors:   Hutchison Medipharma Limited;   BeiGene Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials